Liquid Biopsy in Hepatocellular Carcinoma

Zheyu Zhou; Xiaoliang Xu; Yang Liu; Qiaoyu Liu; Wenjie Zhang; Kun Wang; Jincheng Wang; Yin Yin

doi:10.1007/978-1-0716-3346-5_14

Liquid Biopsy in Hepatocellular Carcinoma

Methods Mol Biol. 2023:2695:213-225. doi: 10.1007/978-1-0716-3346-5_14.

Authors

Zheyu Zhou^{1

2}, Xiaoliang Xu^{2

3}, Yang Liu³, Qiaoyu Liu³, Wenjie Zhang³, Kun Wang³, Jincheng Wang^{2

3}, Yin Yin²

Affiliations

¹ Department of General Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China.
² Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
³ Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

PMID: 37450121
DOI: 10.1007/978-1-0716-3346-5_14

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly neoplasms with a poor prognosis. Due to the significant tumor heterogeneity of HCC, alpha-fetoprotein (AFP) or liver biopsy has not yet met the clinical needs in terms of early diagnosis or determining prognosis. In recent years, liquid biopsy techniques that analyze tumor by-products released into the circulation have shown great potential. Its ability to monitor tumors in real time and respond to their global characteristics is expected to improve the management of HCC patients clinically. This review discusses some of the findings of a liquid biopsy in terms of diagnosis and prognosis of HCC.

Keywords: Biomarkers; Cell-free DNA; Circulating tumor cells; Diagnosis; Extracellular vesicles; Hepatocellular carcinoma; Liquid biopsy; Prognosis.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Carcinoma, Hepatocellular* / diagnosis
Carcinoma, Hepatocellular* / pathology
Humans
Liquid Biopsy
Liver Neoplasms* / diagnosis
Liver Neoplasms* / pathology
alpha-Fetoproteins / analysis

Substances

alpha-Fetoproteins
Biomarkers, Tumor